Clinical Trial Update: Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma [Phase 1, Phase 2]

View source ↗

Summary

The National Cancer Institute–sponsored Phase 1/2 trial evaluating carfilzomib with stem cell transplantation for plasma cell myeloma was terminated, with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Kyprolis (carfilzomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma, Leukemia, Plasma Cell | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-02-03